the weak link for RAC has always been that it didn’t have a drug in a suitable form to take to the clinic for any condition other than AML.
Reformulating bisantrene into 220 version so it is ready for clinical trials has, and is still taking, forever….
in hindsight, the best way RAC could have spent money might have been to throw everything into speeding up the creation of version 220.
…because no clinically suitable drug means no clinical trials….and ASX-listed biotech that can’t do clinical trials don’t get much pricing respect from investors.
Ann: Race Strategic Update August 2023, page-15
-
- There are more pages in this discussion • 578 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
0.040(2.93%) |
Mkt cap ! $239.3M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.50 | $1.35 | $167.2K | 118.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3547 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 2072 | 1 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |